Literature DB >> 12506093

Inhibitory effects of antithrombin III on interactions between blood cells and endothelial cells during retinal ischemia-reperfusion injury.

Kazuaki Nishijima1, Junichi Kiryu, Akitaka Tsujikawa, Megumi Honjo, Atsushi Nonaka, Kenji Yamashiro, Hiroshi Kamizuru, Yoshiaki Ieki, Hidenobu Tanihara, Yoshihito Honda, Yuichiro Ogura.   

Abstract

PURPOSE: Infiltrating leukocytes have long been widely thought to be key mediators of ischemia-reperfusion injury. Recently, however, evidence suggests that platelets accumulating in postischemic tissues also contribute to ischemia-reperfusion injury because of their inflammatory properties and promotion of formation of thrombi. This study was designed to evaluate quantitatively the inhibitory effects of antithrombin (AT)-III on the interactions between blood cells and retinal endothelial cells in vivo after transient retinal ischemia.
METHODS: Transient retinal ischemia was induced for 60 minutes in male Long-Evans rats by ligation of the optic nerve. AT III (250 U/kg) was administered intravenously just after induction of ischemia. Leukocyte and platelet behavior in the retina was evaluated in vivo with a scanning laser ophthalmoscope. Expression of P-selectin and intracellular adhesion molecule (ICAM)-1 in the postischemic retina was investigated by reverse transcription-polymerase chain reaction and immunohistochemistry. After 14 days of reperfusion, ischemia-induced retinal damage was evaluated histologically.
RESULTS: Administration of AT III significantly inhibited leukocyte rolling along the major retinal veins and subsequent accumulation of leukocytes in the postischemic retina. Furthermore, the maximum number of rolling and adherent platelets was reduced by 76% (P < 0.01) and 48% (P < 0.01), respectively, at 12 hours after reperfusion. Immunohistochemical studies also revealed the suppressive effect of AT III on expression of P-selectin and ICAM-1. Finally, histologic examination demonstrated the protective effects of AT III against retinal damage after transient retinal ischemia.
CONCLUSIONS: This study demonstrates the inhibitory effects of AT III on leukocyte and platelet recruitment to the postischemic retina, which may account for the neuroprotective properties of this alpha-2 globulin against retinal ischemia-reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12506093     DOI: 10.1167/iovs.02-0493

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

1.  Vitreous inflammatory factors in macular edema with central retinal vein occlusion.

Authors:  Hidetaka Noma; Hideharu Funatsu; Seiyo Harino; Tatsuya Mimura; Shuichiro Eguchi; Sadao Hori
Journal:  Jpn J Ophthalmol       Date:  2011-05-03       Impact factor: 2.447

2.  HS3ST1 genotype regulates antithrombin's inflammomodulatory tone and associates with atherosclerosis.

Authors:  Nicole C Smits; Takashi Kobayashi; Pratyaksh K Srivastava; Sladjana Skopelja; Julianne A Ivy; Dustin J Elwood; Radu V Stan; Gregory J Tsongalis; Frank W Sellke; Peter L Gross; Michael D Cole; James T DeVries; Aaron V Kaplan; John F Robb; Scott M Williams; Nicholas W Shworak
Journal:  Matrix Biol       Date:  2017-01-23       Impact factor: 11.583

3.  Increase of aqueous inflammatory factors in macular edema with branch retinal vein occlusion: a case control study.

Authors:  Hidetaka Noma; Hideharu Funatsu; Tatsuya Mimura; Katsunori Shimada
Journal:  J Inflamm (Lond)       Date:  2010-08-26       Impact factor: 4.981

4.  Comparison of the efficacy of intravitreal triamcinolone acetonide for cystoid macular edema with versus without serous retinal detachment in branch retinal vein occlusion: influence on macular sensitivity and morphology.

Authors:  Hidetaka Noma; Hideharu Funatsu; Tatsuya Mimura; Katsunori Shimada
Journal:  BMC Ophthalmol       Date:  2012-08-09       Impact factor: 2.209

5.  Antithrombin significantly influences platelet adhesion onto immobilized fibrinogen in an in-vitro system simulating low flow.

Authors:  Robert Loncar; Uwe Kalina; Volker Stoldt; Volker Thomas; Rüdiger E Scharf; Aleksandar Vodovnik
Journal:  Thromb J       Date:  2006-10-13

Review 6.  Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation.

Authors:  Toshiaki Iba; Daizoh Saitoh
Journal:  J Intensive Care       Date:  2014-12-31

7.  Circulating endothelial cells in patients with venous thromboembolism and myeloproliferative neoplasms.

Authors:  Cláudia Torres; Ana Mafalda Fonseca; Magdalena Leander; Rui Matos; Sara Morais; Manuel Campos; Margarida Lima
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

Review 8.  The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases.

Authors:  Francisco J Ascaso; Valentín Huerva; Andrzej Grzybowski
Journal:  Mediators Inflamm       Date:  2014-07-22       Impact factor: 4.711

9.  Aqueous flare and inflammatory factors in macular edema with central retinal vein occlusion: a case series.

Authors:  Hidetaka Noma; Tatsuya Mimura; Maria Tatsugawa; Katsunori Shimada
Journal:  BMC Ophthalmol       Date:  2013-12-11       Impact factor: 2.209

10.  Minocycline prevents retinal inflammation and vascular permeability following ischemia-reperfusion injury.

Authors:  Steven F Abcouwer; Cheng-Mao Lin; Sumathi Shanmugam; Arivalagan Muthusamy; Alistair J Barber; David A Antonetti
Journal:  J Neuroinflammation       Date:  2013-12-10       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.